Welcome to our dedicated page for Promis Neuroscie news (Ticker: PMN), a resource for investors and traders seeking the latest updates and insights on Promis Neuroscie stock.
ProMIS Neurosciences Inc. (Nasdaq: PMN) is a clinical-stage biotechnology company developing therapeutic antibodies and vaccines that selectively target toxic misfolded protein oligomers in neurodegenerative and other misfolded protein diseases. News about ProMIS frequently centers on its lead Alzheimer’s disease program, PMN310, and the company’s biomarker-driven clinical strategy.
Investors following PMN can expect regular updates on the PRECISE-AD Phase 1b trial of PMN310 in early Alzheimer’s disease. Company releases describe PRECISE-AD as a randomized, double-blind, placebo-controlled, multiple ascending dose study evaluating safety, tolerability, pharmacokinetics and biomarker effects of PMN310 in patients with mild cognitive impairment due to AD and mild AD. News items have highlighted enrollment milestones, DSMB recommendations to proceed to higher dose cohorts, and reports that no amyloid-related imaging abnormalities (ARIA) or treatment-related serious adverse events were observed in the cohorts discussed.
ProMIS also issues news on peer-reviewed publications and scientific analyses related to its approach. Recent communications describe publications on the relationship between antibody selectivity for soluble amyloid-beta oligomers and clinical efficacy, as well as analyses supporting plasma phosphorylated tau (pTau) as a potential early predictor of clinical benefit. These publications are referenced by the company as supporting its focus on oligomer-only targeting and its use of plasma pTau as a central endpoint in PRECISE-AD.
Additional PMN news covers corporate and regulatory developments, including the granting of FDA Fast Track designation for PMN310, participation in healthcare investment conferences, board appointments, and capital markets actions such as a one-for-twenty-five reverse stock split and at-the-market offering arrangements. Together, these updates provide context on ProMIS Neurosciences’ clinical progress, scientific rationale and financing activities for those tracking PMN stock and its Alzheimer’s and broader neurodegeneration pipeline.
Summary not available.
Summary not available.
ProMIS Neurosciences (TSX: PMN, Nasdaq: PMN) recently showcased preclinical data supporting its Aβ vaccine candidate aimed at preventing Alzheimer’s disease (AD) progression. The findings were presented at the AAN 2023 Annual Meeting, highlighting the vaccine’s potential advantages over traditional antibody treatments, including sustained efficacy, fewer required doses, and reduced risks of inflammatory responses. The computationally designed vaccine targets misfolded Aβ oligomers—key drivers of AD—showing promising immune responses in mouse models. No adverse T helper responses were observed, and the vaccine selectively activated antibodies against toxic oligomers, potentially minimizing risks associated with plaque-binding antibodies. ProMIS’s focus remains on developing an effective AD vaccine to combat neurodegenerative diseases.
Summary not available.
ProMIS Neurosciences Inc. (TSX: PMN; Nasdaq: PMN) announced the submission of an Investigational New Drug (IND) application to the FDA for PMN310, targeting Alzheimer’s disease (AD). This is a significant milestone in advancing PMN310 towards clinical trials, offering potential new treatment options for AD patients. PMN310 selectively targets toxic oligomers of amyloid-beta, a key factor in AD pathology, showing strong binding to these harmful proteins in preclinical studies. The company anticipates transitioning to a clinical-stage entity pending regulatory approval. Management emphasizes the antibody's potential for a differentiated safety profile compared to existing treatments, which often bind to non-targeted plaques, potentially minimizing associated risks.
ProMIS Neurosciences (TSX: PMN) has announced promising results for its lead candidate, PMN310, which targets toxic oligomers linked to Alzheimer’s disease (AD). In a recent presentation at the AD/PD 2023 conference, new preclinical data showed PMN310 selectively binds to these harmful oligomers, differentiating it from other amyloid-beta-directed antibodies. This selectivity may reduce the risk of side effects commonly associated with plaque-binding therapies. ProMIS plans to submit an IND application in the coming weeks for clinical development of PMN310, aiming to advance its treatment options for patients suffering from AD.
ProMIS Neurosciences Inc. (TSX: PMN, Nasdaq: PMN), a biotechnology company specializing in antibody therapeutics for neurodegenerative diseases, announced presentations at the upcoming American Academy of Neurology Annual Meeting, scheduled for April 22-27, 2023, in Boston, MA. The event will feature an oral presentation and two poster presentations on their drug development pipeline, including lead candidate PMN310 for Alzheimer's disease, a new Alzheimer's vaccine, and potential therapeutic target RACK1 for ALS. Dr. Johanne Kaplan will present on the rational design of vaccines and antibody protection against amyloid-beta oligomers.
ProMIS Neurosciences (TSX: PMN, Nasdaq: PMN) announced new preclinical data for its lead Alzheimer's candidate, PMN310, to be presented at the AD/PD 2023 conference from March 28 to April 1, 2023. The presentation, titled 'Differentiation of PMN310 from Other Amyloid-Beta-Directed Antibodies,' will highlight PMN310's selective targeting of toxic brain oligomers. The virtual poster will be accessible during the conference and on ProMIS’ website, emphasizing the company's commitment to developing antibody therapeutics for neurodegenerative diseases. This data could have significant implications for Alzheimer's treatment.
ProMIS Neurosciences (TSX: PMN, Nasdaq: PMN) announced key developments related to its Alzheimer's disease candidate, PMN310, including the completion of preclinical studies and preparations for an IND submission to the FDA within 60 days. The company reported a significant increase in R&D expenses, totaling $16.1 million for 2022, up from $4.6 million in 2021. General and Administrative expenses rose to $7.3 million, compared to $3.7 million in the previous year. The net loss for 2022 was $18.1 million, reflecting the company's investment in advancing its drug development pipeline.
ProMIS Neurosciences Inc. (TSX: PMN, Nasdaq: PMN), a biotechnology firm focused on antibody therapeutics for neurodegenerative diseases, has announced that CEO Gail Farfel, Ph.D., will present at the Oppenheimer 33rd Annual Conference on March 13, 2023, at 12:30 p.m. ET. The presentation will be webcasted and available on ProMIS’ website for 30 days following the event.
The company specializes in targeting toxic misfolded proteins linked to conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis, and multiple system atrophy. ProMIS employs proprietary platforms to discover novel antibody therapeutics.
FAQ
What is the current stock price of Promis Neuroscie (PMN)?
What is the market cap of Promis Neuroscie (PMN)?
